Skip to main content

Advertisement

Table 2 Changes of disease activity and HAQ-DI in EST and NEW patients (median (25th and 75th percentile))

From: Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria

  EST (n = 284) NEW (n = 62)
baseline after 1 year baseline after 1 year
DAS28 2.67 (1.99, 3.70) 2.58 (1.80, 3.45) 4.46 (3.77, 5.35) 2.43 (1.54, 3.57)
DAS28 Diff   0.18 (-0.47, 0.87)   1.92 (0.65, 2.99)
RADAI-5 2.6 (1.2, 4.4) 2.2 (1.0, 4.0) 4.4 (3.2, 6.2) 2.4 (1.2, 3.8)
RADAI-5 Diff   0.2 (-0.5, 1.2)   2.0 (0.6, 3.4)
HAQ 0.63 (0.13, 1.19) 0.63 (0.13, 1.13) 1.00 (0.63, 1.38) 0.50 (0.13, 1.25)
HAQ Diff   0.00 (-0.13, 0.25)   0.38 (0.00, 0.63)
  1. Abbreviations: DAS28 Disease Activity Score using ESR out of 28 joints, DIFF Difference to baseline after 1 year follow up, ESR Erythrocyte Sedimentation Rate, EST pts with established bDMARD treatment before inclusion in BIOREG of whom a full data set as described is viable, HAQ-DI Health Assessment Questionnaire Disability Index, N number of pts, NEW pts included in BIOREG with start of biologic treatment ± 30 days of whom a full data set as described is viable, PTS patients, RADAI-5 Rheumatoid Arthritis Disease Activity Index-5